• Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.50
▲ +0.02 (0.27%)

This chart shows the closing price for ICCC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmuCell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICCC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICCC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for ImmuCell in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.50.

This chart shows the closing price for ICCC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in ImmuCell.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/23/2022AegisReiterated RatingBuyLow
2/15/2021AegisReiterated RatingBuyMedium
7/13/2020AegisInitiated CoverageBuy$14.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/11/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ImmuCell logo
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.
Read More

Today's Range

Now: $7.50
Low: $7.50
High: $7.63

50 Day Range

MA: $6.91
Low: $6.09
High: $7.84

52 Week Range

Now: $7.50
Low: $5.98
High: $10.96

Volume

449 shs

Average Volume

4,222 shs

Market Capitalization

$58.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmuCell?

The following Wall Street sell-side analysts have issued research reports on ImmuCell in the last year: Aegis, and TheStreet.
View the latest analyst ratings for ICCC.

What is the current price target for ImmuCell?

0 Wall Street analysts have set twelve-month price targets for ImmuCell in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ImmuCell in the next year.
View the latest price targets for ICCC.

What is the current consensus analyst rating for ImmuCell?

ImmuCell currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICCC will outperform the market and that investors should add to their positions of ImmuCell.
View the latest ratings for ICCC.

What other companies compete with ImmuCell?

How do I contact ImmuCell's investor relations team?

ImmuCell's physical mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company's listed phone number is (207) 878-2770 and its investor relations email address is [email protected] The official website for ImmuCell is www.immucell.com. Learn More about contacing ImmuCell investor relations.